These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33426467)

  • 41. Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19.
    Saravanan M; Mostafavi E; Vincent S; Negash H; Andavar R; Perumal V; Chandra N; Narayanasamy S; Kalimuthu K; Barabadi H
    Microb Pathog; 2021 Jul; 156():104908. PubMed ID: 33932543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The emergence of Covid-19: evolution from endemic to pandemic.
    Ahsan H; Arif A; Ansari S; Khan FH
    J Immunoassay Immunochem; 2022 Jan; 43(1):22-32. PubMed ID: 34672900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nanotechnology-Based Approach to Combat Pandemic COVID 19: A Review.
    Shukla BK; Tyagi H; Bhandari H; Garg S
    Macromol Symp; 2021 Jun; 397(1):2000336. PubMed ID: 34511843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic.
    Gulati A; Pomeranz C; Qamar Z; Thomas S; Frisch D; George G; Summer R; DeSimone J; Sundaram B
    Am J Med Sci; 2020 Jul; 360(1):5-34. PubMed ID: 32620220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
    Constantin AM; Noertjojo K; Sommer I; Pizarro AB; Persad E; Durao S; Nussbaumer-Streit B; McElvenny DM; Rhodes S; Martin C; Sampson O; Jørgensen KJ; Bruschettini M
    Cochrane Database Syst Rev; 2024 Apr; 4(4):CD015112. PubMed ID: 38597249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2 in environmental perspective: Occurrence, persistence, surveillance, inactivation and challenges.
    Mohan SV; Hemalatha M; Kopperi H; Ranjith I; Kumar AK
    Chem Eng J; 2021 Feb; 405():126893. PubMed ID: 32901196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.
    Dashraath P; Wong JLJ; Lim MXK; Lim LM; Li S; Biswas A; Choolani M; Mattar C; Su LL
    Am J Obstet Gynecol; 2020 Jun; 222(6):521-531. PubMed ID: 32217113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus.
    Wu Z; Harrich D; Li Z; Hu D; Li D
    Rev Med Virol; 2021 Mar; 31(2):e2171. PubMed ID: 33350025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment.
    Souri M; Chiani M; Farhangi A; Mehrabi MR; Nourouzian D; Raahemifar K; Soltani M
    Nanomaterials (Basel); 2022 Feb; 12(5):. PubMed ID: 35269270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples: Protocol to Validate the Sufficiency of Provider-Observed, Home-Collected Blood, Saliva, and Oropharyngeal Samples.
    Sullivan PS; Sailey C; Guest JL; Guarner J; Kelley C; Siegler AJ; Valentine-Graves M; Gravens L; Del Rio C; Sanchez TH
    JMIR Public Health Surveill; 2020 Apr; 6(2):e19054. PubMed ID: 32310815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanotechnology as a Shield against COVID-19: Current Advancement and Limitations.
    Rai M; Bonde S; Yadav A; Bhowmik A; Rathod S; Ingle P; Gade A
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34202815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives.
    Yayehrad AT; Siraj EA; Wondie GB; Alemie AA; Derseh MT; Ambaye AS
    Int J Nanomedicine; 2021; 16():5713-5743. PubMed ID: 34465991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COVID-19: Progress in diagnostics, therapy and vaccination.
    Liu X; Liu C; Liu G; Luo W; Xia N
    Theranostics; 2020; 10(17):7821-7835. PubMed ID: 32685022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?
    Peeri NC; Shrestha N; Rahman MS; Zaki R; Tan Z; Bibi S; Baghbanzadeh M; Aghamohammadi N; Zhang W; Haque U
    Int J Epidemiol; 2020 Jun; 49(3):717-726. PubMed ID: 32086938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hard Nanomaterials in Time of Viral Pandemics.
    Reina G; Peng S; Jacquemin L; Andrade AF; Bianco A
    ACS Nano; 2020 Aug; 14(8):9364-9388. PubMed ID: 32667191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. All Surfaces Are Not Equal in Contact Transmission of SARS-CoV-2.
    Xue X; Ball JK; Alexander C; Alexander MR
    Matter; 2020 Nov; 3(5):1433-1441. PubMed ID: 33043292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanotechnology Responses to COVID-19.
    Ruiz-Hitzky E; Darder M; Wicklein B; Ruiz-Garcia C; Martín-Sampedro R; Del Real G; Aranda P
    Adv Healthc Mater; 2020 Oct; 9(19):e2000979. PubMed ID: 32885616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.